Tianjin Pharmaceutical Da Ren Tang (SGX:T14) said it has returned 350 million yuan to its designated accounts, according to a Friday filing on the Singapore Exchange.
This amount, temporarily used for cash flow purposes under the fiscal year 2023 temporary use, was utilized as approved by the board.
The company confirmed that the funds were returned as scheduled and informed the placement agent accordingly. This follows the board's resolution during the financial year ended Dec 31, 2023, to use the proceeds for up to 12 months before repayment.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments